Catabasis and Sarepta Engage in joint Research

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) is a clinical stage biopharmaceutical company (“Catbasis”) and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of inventive RNA-targeted therapeutics (“Sarepta”), has announced today a duo research collaboration to probe the possibility of a combination drug treatment approach to deal with Duchenne muscular dystrophy (DMD).

“We are excited to work with Sarepta on this joint research collaboration, which to our knowledge is the first time two companies are testing a combination of investigational therapies to treat Duchenne. We think there is benefit to exploring innovative ways to make the most meaningful difference in this devastating disease”, said Jill C. Milne, Ph.D., chief executive officer of Catabasis.

Both companies will contribute their respective insight to study Duchenne closely via mouse models of DMD by pursuing an approach between Sarepta’s exon skipping treatment and Catabasis’ oral NF-kB inhibition treatment.

Leave a Comment